Metabolic disposition of antipyrine in patients with lung cancer.

Abstract

The metabolism of antipyrine (10 mg/kg i.v.) was studied in nine patients with cancer of the lung and in a cancer-free control group matched for age, sex, drug intake, and smoking and drinking history. The mean plasma clearance of antipyrine was 0.0475 +/- 0.009 liter/kg/hr in the tumor group and 0.0557 +/- 0.007 liter/kg/hr in the control group (p greater than 0.05). The antipyrine plasma elimination half-life was longer in the group with tumors (9.5 +/- 1.3 hr) compared to the control group (7.7 +/- 1.3 hr), but the difference was not statistically significant (p greater than 0.05). There was no difference between the groups in the excretion of two major antipyrine metabolites, 4-hydroxyantipyrine and N-demethylantipyrine, in a 48-hr urine sample. Thus, the presence of lung cancer in humans does not significantly alter antipyrine elimination.

• Authors: C Tschanz, C E Hignite, D H Huffman, D L Azarnoff
• Journal: Cancer research (Cancer Res) Vol. 37 Issue 11 Pg. 3881-6 (Nov 1977) ISSN: 0008-5472 [Print] United States
• PMID: 908027 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)

Chemical References

• 4-hydroxyantipyrine
• N-demethylantipyrine
• Antipyrine

Topics

• Adult
• Aged
• Antipyrine (analogs & derivatives, analysis, metabolism)
• Female
• Humans
• Lung Neoplasms (blood, metabolism, urine)
• Male
• Metabolic Clearance Rate
• Middle Aged